# Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

> **NCT02471716** · PHASE1,PHASE2 · COMPLETED · sponsor: **Five Prime Therapeutics, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Pigmented Villonodular Synovitis
- Tenosynovial Giant Cell Tumor

## Interventions

- **BIOLOGICAL:** FPA008

## Key facts

- **NCT ID:** NCT02471716
- **Lead sponsor:** Five Prime Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471716, "Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02471716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*